全文获取类型
收费全文 | 12636篇 |
免费 | 1077篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 111篇 |
儿科学 | 374篇 |
妇产科学 | 430篇 |
基础医学 | 2091篇 |
口腔科学 | 211篇 |
临床医学 | 1135篇 |
内科学 | 2881篇 |
皮肤病学 | 405篇 |
神经病学 | 1292篇 |
特种医学 | 248篇 |
外国民族医学 | 1篇 |
外科学 | 1636篇 |
综合类 | 76篇 |
一般理论 | 8篇 |
预防医学 | 1015篇 |
眼科学 | 231篇 |
药学 | 795篇 |
中国医学 | 32篇 |
肿瘤学 | 808篇 |
出版年
2023年 | 131篇 |
2022年 | 320篇 |
2021年 | 571篇 |
2020年 | 283篇 |
2019年 | 449篇 |
2018年 | 508篇 |
2017年 | 331篇 |
2016年 | 382篇 |
2015年 | 421篇 |
2014年 | 535篇 |
2013年 | 620篇 |
2012年 | 882篇 |
2011年 | 930篇 |
2010年 | 525篇 |
2009年 | 464篇 |
2008年 | 698篇 |
2007年 | 708篇 |
2006年 | 620篇 |
2005年 | 580篇 |
2004年 | 489篇 |
2003年 | 444篇 |
2002年 | 404篇 |
2001年 | 236篇 |
2000年 | 239篇 |
1999年 | 235篇 |
1998年 | 90篇 |
1997年 | 90篇 |
1996年 | 72篇 |
1995年 | 58篇 |
1994年 | 45篇 |
1993年 | 36篇 |
1992年 | 131篇 |
1991年 | 122篇 |
1990年 | 114篇 |
1989年 | 103篇 |
1988年 | 123篇 |
1987年 | 93篇 |
1986年 | 96篇 |
1985年 | 66篇 |
1984年 | 56篇 |
1983年 | 41篇 |
1982年 | 30篇 |
1981年 | 31篇 |
1980年 | 27篇 |
1979年 | 37篇 |
1978年 | 26篇 |
1977年 | 30篇 |
1976年 | 34篇 |
1974年 | 41篇 |
1973年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
4.
Susan C. Fox Jane A. May Natalia Dovlatova Jackie R. Glenn Andrew Johnson Ann E. White 《Platelets》2019,30(3):290-295
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel. The comparators were light transmission aggregometry (LTA), VerifyNow and Multiplate aggregometry (for determining the effects of aspirin) and LTA, VerifyNow and Multiplate together with the BioCytex VASP phosphorylation assay (for the P2Y12 antagonists). The P-selectin Aspirin Test revealed substantial inhibition of platelet function in all but three of 96 patients receiving aspirin with clopidogrel and in none of 51 patients receiving aspirin and prasugrel. The results were very similar to those obtained using LTA. There was only one patient with high residual platelet aggregation and low P-selectin expression. The same patients identified as “non-responders” to aspirin also presented with the highest residual platelet activity as measured using the VerifyNow system, although not quite as well separated from the other values. With the Multiplate test only one of these patients clearly stood out from the others. The results obtained using the P-selectin P2Y12 Test in 102 patients taking aspirin and clopidogrel were similar to the more traditional approaches in that a wide scatter of results was obtained. Generally, high values seen with the P-selectin P2Y12 Test were also high with the LTA, VerifyNow, Multiplate, and BioCytex VASP P2Y12 Tests. Similarly, low residual platelet function using the P2Y12 test was seen irrespective of the testing procedure used. However, there were differences in some patients. Prasugrel was always more effective than clopidogrel in inhibiting platelet function with none of 56 patients (P-selectin and VerifyNow), only 2 of 56 patients (Multiplate) and only 3 of 56 patients (Biocytex VASP) demonstrating high on-treatment residual platelet reactivity (HRPR) defined using previously published cut-off values. The exception was LTA where there were 11 of 56 patients with HRPR. It remains to be seen which experimental approach provides the most useful information regarding outcomes after adjusting therapies in treated patients. 相似文献
5.
6.
7.
A. Armentia S. Martín-Armentia A. Moral D. Montejo B. Martin-Armentia R. Sastre S. Fernández A. Corell D. Fernandez 《Allergologia et immunopathologia》2019,47(4):350-356
Introduction and objectivesBiological aerosols play a vital role in the interactions between the atmosphere, biosphere, climate and public health and fungal spores are a component with allergic importance.We constructed a database in Castile & Leon (Spain) and carry out molecular-level component-resolved diagnosis to complete the air quality study carried out since 2006 by our aerobiological network (RACYL) to aid clinical diagnosis and treatment.MethodsWe reviewed a database of 19,774 patients (adults and children) with allergic respiratory disease treated in our unit during the last 12 years. We also made a component-resolved diagnosis of the molecules involved in the pathology in a randomly selected population of 150 patients.ResultsThe dimeric glycoprotein Alt a1 from Alternaria is the most prevalent and most useful allergen in the diagnosis of patients with allergy to fungi in our area (94.4%), followed by enolase Alt a 6 (Alternaria), ribonuclease Asp f 1 of Aspergillus and mannitol dehydrogenase from Cla h 8 (Cladosporium).ConclusionsOur results have helped determine which spore molecules are most-closely associated with allergies. Molecular analysis will be useful to determine more accurate and useful immunotherapy in these patients. 相似文献
8.
9.
10.
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation 总被引:2,自引:0,他引:2
Rolf N. Barth Christina A. Janus Christine A. Lillesand Nancy A. Radke John D. Pirsch Bryan N. Becker Luis A. Fernandez L. Thomas Chin Yolanda T. Becker Jon S. Odorico Anthony M. D''Alessandro Hans W. Sollinger Stuart J. Knechtle 《Transplant international》2006,19(11):885-892
Campath-1H (alemtuzumab) induction was used for renal transplantation in combination with sirolimus as immunosuppression. We previously reported a high (28%) rate of early rejection with this regimen, and now report 3-year outcomes. Twenty-nine patients were recipients of either deceased donor or non-HLA (Human Leukocyte Antigen) identical living donor primary renal allografts. Clinical parameters including infection, malignancy, kidney function, and kidney histology were followed prospectively for 3 years. Three-year cumulative graft and patient survival were 96% and 100%, respectively. Twenty patients were maintained on steroid-free immunosuppressive regimens, and 15 patients were maintained on monotherapy for immunosuppression (12 on sirolimus). No serious infectious complications were observed and two patients developed basal cell skin cancer. The 3-year results of our initial pilot study demonstrate good graft (96%) and patient (100%) outcomes. Campath-1H induction has yielded a high proportion of patients maintained on immunosuppressive monotherapy (57%) without serious infectious- and no malignancy-related complications. The reported regimen yielded novel insights into both Campath-1H and sirolimus therapy in renal transplantation. Because of the higher incidence of early rejection, we recommend a modified strategy of immunosuppression including a brief course of a calcineurin inhibitor. 相似文献